Loading
A phase 1/2 trial of GT201 in advanced solid tumours, run by Grit Biotechnology, now recruiting.
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06144671 by Grit Biotechnology, with 78 participants planned, started 2025-11-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: GT201, IL-2 and PD-1 inhibitor.
Shares Grit Bio and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Grit Bio and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.